Disc Medicine Inc. (IRON)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LSE 
Ironveld shares jump 32% at 0.025p as processing plant hits sustained production
Shares in Ironveld PLC (AIM:IRON) jumped 32% to 0.025p after the mining developer said its processing plant had reached sustained production and secured strong commercial demand. Ironveld, an AIM-listed company producing strategic metals for mineral processing, said its dense media separation plant was now running continuously for 16 hours a day on a double shift.
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade
The consensus price target hints at a 48.6% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality
Disc Medicine is well-capitalized, with over $800M in cash, ensuring operational runway through 2029 regardless of bitopertin's launch success. Bitopertin's NDA is submitted, aiming for accelerated FDA approval; if successful, IRON transitions from R&D to commercial stage with significant revenue potential. Phase 2 data for DISC-0974 in myelofibrosis show strong efficacy, especially in synergy with JAK inhibitors, expanding the addressable market and clinical utility.
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript
Disc Medicine, Inc. ( IRON ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025.
Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript
Disc Medicine, Inc. ( IRON ) Stifel 2025 Healthcare Conference November 13, 2025 8:40 AM EST Company Participants Jonathan Yu - Chief Opearating Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division So we're going to go ahead and get started. I'm Steve Willey, one of the senior biotech analysts here at Stifel.
Disc Medicine: Forging Ahead In Hematology
Disc Medicine's strong financial position, with $489.9 million in cash and securities, ensures funding through 2028, reducing near-term financing risks. Lead asset Bitopertin shows promise in treating rare hematologic diseases, with a clear regulatory path and potential accelerated approval by H2 2025. Diversified pipeline includes DISC-0974 for anemia and DISC-3405 for iron overload, offering multiple paths to success in hematologic drug development.
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
